Advertisement

Topics

DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases

07:25 EDT 17 Apr 2019 | Pharmaceutical Business Review

The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in

The post DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases appeared first on Pharmaceutical Business review.

Original Article: DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases

NEXT ARTICLE

More From BioPortfolio on "DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...